Description

SkinGest™ PSOR - A new generation in natural skin care

Supports normal immune functions 
to maintain healthy skin (oral use)

HEALTH CANADA ISSUED A NATURAL PRODUCT NUMBER (NPN) FOR DERMYLEX (SkinGest™ PSOR)

The bioactive profile of SkinGest™ PSOR is related to the presence of growth factors, active peptides and immunoglobulins in the extract.

SkinGest™ PSOR is a unique, patented, highly purified and non-GMO whey protein isolate with multifunctional properties. It promotes the natural and balanced immune functions of the skin. The bioactive profile of SkinGest™ PSOR is related to the presence of standardized growth factors, active peptides and immunoglobulins in the extract. SkinGest™ PSOR acts by reducing T-cell activity promoting healthy keratinocytes and fibroblast responses.

Life Quality Index scores, as well as itching sensation, decreased significantly at the end of the usage period for patients taking SkinGest™ PSOR compared to placebo.

SkinGest™ PSOR represents a natural health product to be used as supportive oral cosmeceutical treatment for mild-to-moderate skin irritations, but is not intended for substitution of physician-prescribed remedies.

Two clinical trials, including a 112-day, multi-center, double-b lind, placebo-controlled trial with 84 patients, clinically proved the efficacy and safety of SkinGest™ PSOR.

Download PDF - SkinGest™ PSOR Product Sheet

Clinical Studies

Study I: Open-label

• Poulin Y, Pouliot Y, Lamiot E, Aattouri N, Gauthier SF. Safety and efficacy of a milk-derived extract in the treatment of plaque psoriasis: an open-label study. J Cutan Med Surg 9(6): 271-7, 2005

Study II and III: Double-blind against placebo

• Poulin Yet al. XP-828L*(SkinGest™ PSOR)  in the treatment of mild-to-moderate psoriasis: A randomized, double blind placebo-controlled study. J Cutan Med Surg 10(5): 241-8, 2006
• Drouin R et al. XP-828L* (SkinGest™ PSOR), a new whey protein extract for the treatment of mild to moderate psoriasis.  Can J Physiol Pharmacol 85: 943-51, 2007
• Drouin R et al. A double-blind placebo controlled randomized trial of XP-828L (SkinGest™ PSOR) (800 mg) on the quality of life and the clinical symptoms of patients with mild-to-moderate psoriasis. Alt Med Rev 13(2), 2008

Clinical Results

PASI* scores significantly improved by 25% or higher in 38% of the patients at day 56 (vs 0% for placebo, P<0.05)

Itching sensation decreased by 25% or higher in 31% of the patient at day 56, compared to 10% in placebo, P<0.05.

*Psoriasis area severity index

Regulatory Approval & Health Claim

• Unique complex (SkinGest™ PSOR) maintains healthy cytokines levels and inflammatory process.
• Supports normal immune functions to maintain skin health.
• Natural support for healthy skin and immune functions.
• Natural support for healthy skin.

*These statements have not been evaluated by the Food and Drug Administration (FDA).
The product is not intended to diagnose, treat, cure or prevent any disease.
SkinGest is a trademark of P.L. Thomas

ResearchLiteratureMedia Center